Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
167 hot topic(s) found with the query "Personalized medicine"

Personalized Medicine in Kidney Disease
G Gembilo et al, JPM, October 16, 2023 (Posted: Oct 17, 2023 9AM)

From the abstract: "Personalized medicine uses the phenotypes and genotypes of individuals to tailor the best therapeutic approach for each patient at the appropriate time, to identify a person’s propensity for disease, and/or to provide timely and targeted prevention. In the context of kidney diseases, it has the potential to completely transform patient care on the basis of individual traits and needs. In particular, personalized medicine approaches in chronic kidney disease (CKD) aim to tailor treatment strategies based on underlying causes, genetic factors, the rate of disease progression, and other personalized factors. "

Age-dependent topic modeling of comorbidities in UK Biobank identifies disease subtypes with differential genetic risk.
Xilin Jiang et al. Nat Genet 2023 10 (Posted: Oct 10, 2023 9AM)

From the abstract: " The analysis of longitudinal data from electronic health records (EHRs) has the potential to improve clinical diagnoses and enable personalized medicine, motivating efforts to identify disease subtypes from patient comorbidity information. Here we introduce an age-dependent topic modeling (ATM) method that provides a low-rank representation of longitudinal records of hundreds of distinct diseases in large EHR datasets. "

A Revolution Is Coming to Medicine. Who Will It Leave Out?
J Tabery, NY Times, August 5, 2023 (Posted: Aug 07, 2023 9AM)

There are some diseases for which genetics is truly saving lives; in particular, patients with rare diseases like spinal muscular atrophy and certain cancers such as chronic myelogenous leukemia may now be prescribed personalized medicine treatments that simply didn’t exist a couple of decades ago. For most patients with most diseases, though, the lofty promises have failed to materialize.

What doctors wish patients knew about precision medicine
AMA News Wire, July 2023 (Posted: Jul 30, 2023 10AM)

In the rapidly evolving health care landscape, precision medicine—also referred to as personalized medicine—has emerged as a revolutionary approach that tailors medical treatments to individual patients. By harnessing the power of advanced technologies and genetic insights, precision medicine is transforming the way we understand and treat diseases.

Special Issue: “Genetic Counseling and Genetic Testing in Precision Medicine”
E Turbitt et al, J Per Med, July 27, 2023 (Posted: Jul 27, 2023 7AM)

Delivering on the promises of precision medicine comprehensively, equitably, and promptly depends on optimizing health service delivery to facilitate access to timely, evidence-based genetic and genomic testing. Improvements in access to genetic counseling and testing enable the delivery of the ‘right care to the right patient at the right time’. This Special Issue of the Journal of Personalized Medicine showcases the latest research on genetic counseling and genetic testing in precision medicine.

Genotype error due to low-coverage sequencing induces uncertainty in polygenic scoring
E Petter et al, AJHG, July 24, 2023 (Posted: Jul 25, 2023 8AM)

Polygenic scores (PGSs) have emerged as a standard approach to predict phenotypes from genotype data in a wide array of applications from socio-genomics to personalized medicine. Traditional PGSs assume genotype data to be error-free, ignoring possible errors and uncertainties introduced from genotyping, sequencing, and/or imputation. In this work, we investigate the effects of genotyping error due to low coverage sequencing on PGS estimation.

Perspective on 'Harm' in Personalized Medicine.
Aaron L Sarvet et al. Am J Epidemiol 2023 7 (Posted: Jul 23, 2023 9AM)

Avoiding harm is an uncontroversial aim of personalized medicine. However, the precise mathematical translation of “harm” is disputable. Here we use a formal causal language to study common, but distinct, definitions of “harm”. We clarify that commitment to a definition of harm has important practical and philosophical implications for decision making. We relate our practical and philosophical considerations to ideas from medical ethics and legal practice.

Improving polygenic score prediction for coronary artery disease across populations of diverse ancestry
Nature Medicine, July 10, 2023 (Posted: Jul 10, 2023 11AM)

Genome-wide polygenic scores quantify inherited risk by integrating information from many common DNA variants and hold considerable promise for enabling personalized medicine. By integrating information on coronary artery disease (CAD) and CAD-related risk traits from genetic datasets that were larger and more diverse than those used in the past, we developed an improved multi-ancestry polygenic predictor for CAD.

Cost-Effectiveness Analysis of Personalized Hypertension Prevention
ST Wang, J Per Med, June 15, 2023 (Posted: Jun 16, 2023 1PM)

While a population-wide strategy involving lifestyle changes and a high-risk strategy involving pharmacological interventions have been described, the recently proposed personalized medicine approach combining both strategies for the prevention of hypertension has increasingly gained attention. However, a cost-effectiveness analysis has been hardly addressed. The personalized preventive treatment appeared more cost-effective than population-based conventional care. These findings are extremely valuable for making hypertension-based health decisions based on precise preventive medication.

‘The human genome revealed its secrets 20 years ago. It’s time to fulfill its promise of personalized health care’
A Wojicki, Fortune Magazine, April 25, 2023 (Posted: Apr 29, 2023 3PM)

Sequencing the human genome for the first time was an incredible feat. Twenty years ago this week, the sequencing project was completed with the promise that it would transform how we predict, prevent, and treat almost all human disease. With such an important discovery under our belt, one would believe we are now on the cusp of a new phase in personalized healthcare, one that uses genetics to inform every patient journey. Yet, we are still far from the delivery of personalized healthcare for everyone. The problem is not a lack of scientific progress, but rather a failure to implement widespread genetic testing and personalized medicine for all who could benefit from it.

Precision Medicine in Oral Health and Diseases: A Systematic Review
G Malcangi et al, J Per Med, April 25, 2023 (Posted: Apr 25, 2023 7AM)

Precision medicine (PM) is personalized medicine that can develop targeted medical therapies for the individual patient, in which “omics” sciences lead to an integration of data that leads to highly predictive models of the functioning of the individual biological system. They enable rapid diagnosis, assessment of disease dynamics, identification of targeted treatment protocols, and reduction of costs and psychological stress. “Precision dentistry” (DP) is one promising application that need further investigation; the purpose of this paper is therefore to give physicians an overview of the knowledge they need to enhance treatment planning and patient response to therapy.

Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions)
DS Wojtas et al, J Pers Med, February 21, 2023 (Posted: Feb 22, 2023 6AM)

Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation.

An innovative framework to determine the implementation level of personalized medicine: A systematic review
LA Cobos et al, Front in Public Health, February 3, 2023 (Posted: Feb 03, 2023 7AM)

Personalized medicine (PM) is now the new frontier in patient care. The application of this new paradigm extends to various pathologies and different patient care phases, such as diagnosis and treatment. Translating biotechnological advances to clinical routine means adapting health services at all levels is necessary. This article aims to identify the elements for devising a framework that will allow the level of PM implementation in the country under study to be quantitatively and qualitatively assessed and that can be used as a guideline for future implementation plans.

They Created a Drug for Susannah. What About Millions of Other Patients?
EC Hayden et al, NY Times, December 19, 2022 (Posted: Dec 19, 2022 11AM)

Scientists have made rapid progress in customizing drugs for ultrarare diseases. The hard part now is making such treatments on a large scale. Susannah was the first person to receive a drug designed to treat KIF1A-associated neurological disorder, or KAND, a progressive disease caused by genetic mutations that affect just 400 people in the world. In doing so, the young girl and her parents have found themselves on the edge of personalized medicine.

Personalized Medicine and Obstructive Sleep Apnea
SQ Quy et al, J Per Med, December 2022 (Posted: Dec 09, 2022 6AM)

Obstructive sleep apnea (OSA) is a common disease that is often under-diagnosed and under-treated in all ages. This is due to differences in morphology, diversity in clinical phenotypes, and differences in diagnosis and treatment of OSA in children and adults, even among individuals of the same age. This narrative review seeks to describe the current concepts and relevant approaches towards personalized management of patients with OSA, according to pathophysiology, cluster analysis of clinical characteristics, adequate combined therapy, and the consideration of patients’ expectations.

Sepsis as a Challenge for Personalized Medicine
R Zahorek et al, J Per Med, December 1, 2022 (Posted: Dec 01, 2022 3PM)

The remarkable progress in clinical medicine in the field of Sepsis can be attributed to basic research, genomics and proteomics, together with a better understanding of the immunopathology, biology and epidemiology of sepsis syndrome. The aim of this Special Issue is to provide research evidence and potential uses for personalized medicine in Sepsis, highlighting eight papers focused on research achievements in animal and human studies.

Asthma: From Phenotypes to Personalized Medicine
P Bakakos, J Per Med, November 6, 2022 (Posted: Nov 06, 2022 8AM)

Asthma is a heterogeneous disease of the airways with a high prevalence worldwide characterized by chronic inflammation. The aim of asthma management is the control of the disease, and the cornerstone of asthma treatment is inhaled corticosteroids. Asthma is no longer recognized as a unique manifestation, and the “one size fits all” approach may apply only in the treatment of mild asthma.

Readiness to Accept Genetic Testing for Personalized Medicine: Survey Findings on the Role of Socio-Demographic Characteristics, Health Vulnerabilities, Perceived Genetic Risk and Personality Factors
A Leppin et al, J Per Med, November 3, 2022 (Posted: Nov 04, 2022 9AM)

Studies from various countries have shown that majorities would accept genetic testing for personalization of treatment, but little is known about differences among population subgroups. The present study investigated whether readiness to accept a hypothetical cost-free offer of genetic testing to personalize treatment depends on socio-demographic characteristics, health-related vulnerabilities, personal dispositions, and prior awareness about personalized medicine.

Inconsistent clinical practices thwart wider use of personalized medicine
D Pritchard et al, STAT News, October 31, 2022 (Posted: Nov 01, 2022 2PM)

The promise of personalized medicine — safer and more effective treatments tailored to each individual’s body and needs — isn’t being fully met because of challenges associated with its implementation in clinical practice. Gaps in clinical practice that limited the possibility of personalized medicine included failures to order tests to identify genes that may be associated with targeted treatment options, failures to collect the tissue or blood samples needed for those tests, errors in collecting or processing tissue or blood sample, testing results that were inconclusive or provided false negatives, extended turnaround times for reporting results that prompted doctors to prescribe one-size-fits-all treatments for patients who did not have the time to wait any longer, and failures to prescribe the appropriate therapies to patients who tested positive for actionable biomarkers.

Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer.
Sadik Helen et al. JCO precision oncology 2022 10 e2200246 (Posted: Nov 01, 2022 2PM)

For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of 1,000 patients who did receive results from a biomarker test, 147 (29.2%) did not receive appropriate targeted treatments. Thus, approximately 64% of potentially eligible patients with aNSCLC are not benefiting from precision oncology therapies appropriate for their disease.

Building Capacity for Implementation Science in Precision Health and Society: Development of a Course for Professional and Graduate Students in Pharmacy
MC Roberts, J Personalized Medicine, September 14, 2022 (Posted: Sep 14, 2022 3AM)

Training in the field of implementation science is critical for future pharmacists and pharmaceutical scientists to successfully implement precision health interventions in pharmacy practice. We developed an elective course for second- and third-year students at the UNC Eshelman School of Pharmacy to develop foundational knowledge in implementation science with a focus on precision health implementation. The eight-week course used a flipped classroom format featuring lecture videos, suggested readings, quizzes, guest lectures from experts, case studies, and a group project.

Personalized Medicine in Coronary Artery Disease: Where Are We in 2022?
Dmitry Shchekochikhin et al, J Per Medicine, September 1, 2022 (Posted: Sep 01, 2022 2PM)

This Special Issue of the Journal of Personalized Medicine covers several questions about personalized medicine in coronary artery disease, with a special focus on the use of non-coning RNA as biomarkers or treatment targets and novel cardiac imaging modalities that can influence daily practice.

Theranostics could be big business in precision oncology
C Arnold, Nature Medicine, April 19, 2022 (Posted: Apr 20, 2022 7AM)

Theranostics aim to both diagnose and treat cancer. Although few such drugs are on the market, many are being tested in clinical trials, with early results showing promise. The right therapy depends on the right diagnosis. Hippocrates wrote as much more than 2,000 years ago, and physicians have honed their diagnostic ability over the years. In an era of personalized medicine, when treatments can vary based on molecular markers, getting a precise diagnosis is even more crucial. Nowhere in medicine has this become more apparent than in oncology.

How can we address the uncertainties regarding the potential clinical utility of polygenic score-based tests?
Moorthie Sowmiya et al. Personalized medicine 2022 (Posted: Mar 18, 2022 10AM)

Polygenic scores have been developed as the mechanism by which knowledge of common variants can be used to investigate genetic contributions to disease risk. They serve as a biomarker to provide an estimate of the genetic liability for a particular disease. Discussion continues as to whether polygenic scores are a useful biomarker and their readiness for incorporation into clinical and public health practice. In this paper, we investigate the key challenges that need to be addressed, in the description and assessment of the clinical utility of polygenic score-based tests for use in clinical and public health practice.

COVID-19 Surveillance in the Biobank at the Colorado Center for Personalized Medicine
RK Johnson et al, MEDRXIV, February 21, 2022 (Posted: Feb 23, 2022 7AM)

How I faced my prostate cancer: a molecular biologist’s perspective
M Zuradelli, NPJ Precision Oncology, September 2021 (Posted: Sep 28, 2021 6AM)

Hippocrates reminds us that “It is more important to know what sort of person has a disease than to know what sort of disease a person has”. This is still true today and reflects the emerging role of personalized medicine for patient-specific risk stratification and treatment programs. This report documents my personal experience as a patient with aggressive prostate cancer, who, as a scientist, had the privilege to access cutting-edge medical care and molecular profiling.

Large-Scale Population Studies Can as a Path to Personalized Medicine: Easier Said Than Done!
MJ Khoury et al, CDC Blog Post, September 22, 2021 Brand (Posted: Sep 22, 2021 11AM)

It is not surprising that the path to personalized medicine should start with large scale longitudinal population studies. Nevertheless, these studies will take years if not decades to complete, and they are very expensive and complex. Furthermore, they can have methodological pitfalls in selection of participants, measurement of risk factors and outcomes, data standardization and sharing, complex analyses and causal inference. In the meantime, adding implementation science to these studies can inform how best to deploy interventions that can save lives and reduce health disparities.

Genome-Scale Metabolic Modeling of the Human Microbiome in the Era of Personalized Medicine.
Heinken Almut et al. Annual review of microbiology 2021 (Posted: Jul 30, 2021 9AM)

Dermatology Advances Into an Era of Precision Medicine
JY Wang et al, JAMA Dermatology, June 2, 2021 (Posted: Jun 02, 2021 10PM)

Despite the falling costs and increased availability of next-generation sequencing services, the promise of a personalized medicine approach in clinical dermatology has largely remained an abstract ideal. Although standard-of-care therapies and procedures are efficacious for most common cutaneous neoplasms, there is still room for improvement in available treatment options for patients with advanced disease, severe burden of disease, or rare diseases.

Biomarker approach harnessed in trials of personalized medicine for bladder cancer
N Dizman et al, Nature Medicine, May 3, 2021 (Posted: May 03, 2021 0PM)

A multi-arm clinical trial reports results of testing a strategy for the treatment of bladder cancer that uses standard immunotherapy plus biomarker assessment and targeted therapies.

A Quantitative Framework for Measuring Personalized Medicine Integration into US Healthcare Delivery Organizations
A Aqarwal et al, JPM, March 2021 (Posted: Mar 26, 2021 8AM)

In order to address barriers to widespread PM adoption, a comprehensive and methodical approach to assessing the current level of PM integration within a given organization and the broader healthcare system is needed. A quantitative framework encompassing a multifactorial approach to assessing PM adoption has been developed and used to generate a rating of PM integration in 153 organizations across the US.

Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health.
Traversi Deborah et al. Journal of personalized medicine 2021 11(2) (Posted: Mar 09, 2021 9AM)

Race and Pharmacogenomics—Personalized Medicine or Misguided Practice?
CW Goodman et al, JAMA< January 25, 2021 (Posted: Jan 25, 2021 11AM)

Pharmacogenomics poses challenges for researchers, policy makers, and clinicians. Universal screening for genetic predisposition to adverse drug reactions would make race-based algorithms unnecessary, but imperatives to use limited resources judiciously may warrant more selective screening, targeted to high-prevalence groups, if such groups can be identified accurately.

One in Eight Cancer Patients Harbors Inherited Mutation that Increases Risk of Disease Development
Clinical Omics, November 3, 2020 (Posted: Nov 04, 2020 8AM)

In a finding that bolsters the field of personalized medicine, a new large-scale study from the Mayo Clinic reports that one in eight cancer patients they followed had an inherited mutation that increases their risk of developing a malignancy. Further, the study showed that more than half of all patients with such mutations were being missed.

Genome UK: a new National Genomics Healthcare Strategy
P Brice, PHG Foundation, September 26, 2020 (Posted: Oct 01, 2020 9AM)

The much-anticipated National Genomics Healthcare Strategy, has now landed. GENOME UK: The future of healthcare sets out plans to use genomics to drive improvements in diagnosis and personalized medicine; disease prevention; and research. All to be achieved by building on existing major institutions, funding streams and infrastructure.

Time to reality check the promises of machine learning-powered precision medicine
J Wilkinson et al, Lancet Digital Health, September 16, 2020 (Posted: Sep 19, 2020 8PM)

Although the vision of personalized medicine is alluring, there is a need to distinguish genuine potential from hype. We argue that the goal of personalized medical care faces challenges, many of which cannot be addressed through algorithmic complexity, and call for collaboration between traditional methodologists and experts in medical machine learning.

Advances in Genetic Characterization and Genotype–Phenotype Correlation of Duchenne and Becker Muscular Dystrophy in the Personalized Medicine Era
O Sheikh et al, JPM, September 3, 2020 (Posted: Sep 03, 2020 8AM)

To maximize the benefit of exon-skipping therapies, accurate genetic diagnosis and characterization including genotype–phenotype correlation studies are becoming increasingly important. In this article, we present the recent progress in the collection of mutational data and optimization of exon-skipping therapy for DMD/BMD.

Integrating Personalized Medicine With Population Health Management- The Path Forward
DC Grossman et al, July 30, 2020 (Posted: Jul 30, 2020 11AM)

While genomics and personalized medicine may be a key to population health, the way forward will be costly, wasteful, and potentially harmful without the establishment of priorities, adherence to rules of evidence, and the patience to wait for outcomes to unfold over years of observation.

Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers.
Helbig Ingo et al. Neuropharmacology 2020 Jan 172107970 (Posted: May 20, 2020 7AM)

The enduring importance of family health history in the era of genomic medicine and risk assessment.
Haga Susanne B et al. Personalized medicine 2020 Apr (Posted: Apr 29, 2020 7AM)

A review of clinical pharmacogenetics Studies in African populations.
Radouani Fouzia et al. Personalized medicine 2020 Mar (Posted: Mar 11, 2020 8AM)

Bringing Personalized Medicine to Precision Medicine in Gastroesophageal Cancer
J Chao et al, JAMA Network Open, February 14, 2020 (Posted: Feb 17, 2020 10AM)

Advancing Personalized Medicine Through Prediction
AR Localio et al, Annals of Internal Medicine, November 12, 2019 (Posted: Nov 13, 2019 8AM)

A roadmap for familial hypercholesterolemia control
AC Pereira, The Lancet Digital Health, October 2019 (Posted: Nov 04, 2019 8AM)

In an era of personalized medicine, familial hypercholesterolemia is potentially one of the most tractable conditions to deliver the promised society-wide benefits of the implementation of this paradigm. Controlling the disease, however, requires a multipronged approach and the orchestrated participation of several different stakeholders.

Looking back and thinking forwards - 15 years of cardiology and cardiovascular research.
Kalman Jonathan M et al. Nature reviews. Cardiology 2019 Sep (Posted: Oct 21, 2019 10AM)

Several practice-changing breakthroughs are described, such as those that target risk factors such as inflammation and elevated LDL-cholesterol levels. Furthermore, these key opinion leaders predict that machine learning technology and data derived from wearable devices will pave the way towards the coveted goal of personalized medicine.

Toward clinical digital phenotyping: a timely opportunity to consider purpose, quality, and safety
K Huckvale, NPJ Digital Medicine, Septetmber 2019 (Posted: Sep 08, 2019 6AM)

The authors identify four opportunities for research directed toward this goal: exploring intermediate outcomes and underlying disease mechanisms; focusing on purposes that are likely to be used in clinical practice; anticipating quality and safety barriers to adoption; and exploring the potential for digital personalized medicine.

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.
Simeonidis Stavros et al. Frontiers in pharmacology 2019 10830 (Posted: Aug 27, 2019 6PM)

Blockchains for Secure Digitized Medicine.
Shuaib Khaled et al. Journal of personalized medicine 2019 Jul (3) (Posted: Jul 29, 2019 8AM)

Blockchain as an emerging technology has been gaining in popularity. With the offer of a decentralized, distributed environment without the need for a third trusted party (TTP), blockchains are being used in many fields. One possible field that could benefit from blockchains that researchers have been focusing on is digital healthcare.

Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma.
Loft Matthew et al. Journal of personalized medicine 2019 Jul (3) (Posted: Jul 29, 2019 8AM)

The review focuses on the development of ctDNA as a non-invasive liquid biopsy, with potential clinical applications in pancreatic cancer. These include screening, prognostication via the detection of minimal residual disease, early detection of recurrence, and monitoring treatment response.

What will it take to implement genomics in practice? Lessons from the IGNITE Network.
Ginsburg Geoffrey S et al. Personalized medicine 2019 Jul (Posted: Jul 28, 2019 4PM)

While many aspects of implementation science are generic, the unique features of genomic medicine call for adapting current implementation science models to meet the needs of patients, providers and health systems adopting these complex interventions. Since 2013, the IGNITE network has faced numerous challenges. To enable future research, those challenges and our insights for solutions are highlighted.

Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review.
Hendricks-Sturrup Rachele M et al. Journal of personalized medicine 2019 Jul 9(3) (Posted: Jul 10, 2019 8AM)

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
DM Kurtz et al, Cell, July 4, 2019 (Posted: Jul 05, 2019 8AM)

The authors describe the Continuous Individualized Risk Index (CIRI), a method to dynamically determine outcome probabilities for individual patients utilizing risk predictors acquired over time. Similar to ?win probability? models in other fields, CIRI provides a real-time probability by integrating risk assessments throughout a patient?s course. This dynamic risk assessment could facilitate personalized medicine and enable innovative therapeutic paradigms

Educating healthcare providers in the delivery of genomic medicine
J McCarthy et al, Pers Medicine, June 2019 (Posted: Jun 27, 2019 8AM)

Foreword to a special focus issue on genomics education of health care providers. including articles on implementing personalized medicine cancer program in a community cancer system, provider engagement in precision oncology and pharmacogenomic education for health care professionals through electronic educational courses.

Special Focus Issue highlights genetic and genomic education for personalized medicine,
EurekAlert, June 20, 2019 (Posted: Jun 26, 2019 9AM)

The journal Personalized Medicine has released of a Special Focus Issue entitled 'Improving Genomics Education' that highlights the implementation of genetics and genomics education for healthcare providers and the general public. Highlights from the issue include an article investigating provider engagement of genetic education in oncology; a special report highlighting the trends, challenges and importance of undergraduate medical education in genetics and genomics

Artificial Intelligence and Personalized Medicine.
Schork Nicholas J et al. Cancer treatment and research 2019 178265-283 (Posted: Jun 26, 2019 9AM)

Primary Care Physicians' Knowledge, Attitudes, and Experience with Personal Genetic Testing.
Haga Susanne B et al. Journal of personalized medicine 2019 May 9(2) (Posted: Jun 05, 2019 9AM)

Continuous pharmacogenomics and genomic medicine education for healthcare professionals through electronic educational courses.
Tsermpini Evangelia-Eirini et al. Personalized medicine 2019 May (Posted: May 29, 2019 9AM)

Implementing a personalized medicine cancer program in a community cancer system.
Dressler Lynn G et al. Personalized medicine 2019 May (Posted: May 29, 2019 8AM)

The significance of microbiome in personalized medicine.
Behrouzi Ava et al. Clinical and translational medicine 2019 May 8(1) 16 (Posted: May 15, 2019 9AM)

Big data analytics for personalized medicine.
Cirillo Davide et al. Current opinion in biotechnology 2019 Apr 161-167 (Posted: Apr 15, 2019 8AM)

Personalized Medicine and the Power of Electronic Health Records.
Abul-Husn Noura S et al. Cell 2019 Mar 177(1) 58-69 (Posted: Mar 27, 2019 8AM)

Buffalo gave us spicy wings and the ‘book of life.’ Here’s why that’s undermining personalized medicine
S Begley, Stat News, March 11, 2019 (Posted: Mar 13, 2019 8AM)

Personalized medicine in chronic kidney disease by detection of monogenic mutations.
Connaughton Dervla M et al. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019 Feb (Posted: Mar 06, 2019 10AM)

Advancing Personalized Medicine Through the Application of Whole Exome Sequencing and Big Data Analytics
P Sewinski et al, Front in Genetics, February 2019 (Posted: Mar 03, 2019 10AM)

How personalized medicine is transforming your health care
F Smith, National Geographic, January 2019 (Posted: Dec 14, 2018 1PM)

Researchers Develop Personalized Medicine Tool for Inherited Colorectal Cancer Syndrome Risk
Huntsman Cancer Institute, December 10, 2018 (Posted: Dec 11, 2018 11AM)

Personalized medicine tool for inherited colorectal cancer syndrome
Science Daily, December 10, 2018 (Posted: Dec 11, 2018 10AM)

Many Americans Unaware of Promise of Targeted, 'Personalized' Medicine: Poll
D Thompson, US News, December 6, 2018 (Posted: Dec 09, 2018 4PM)

Statistical pitfalls of personalized medicine
S Senn, Nature News, November 27, 2018 (Posted: Nov 28, 2018 9AM)

Patient and Provider Perspectives on a Decision Aid for Familial Hypercholesterolemia.
Farwati Medhat et al. Journal of personalized medicine 2018 Nov 8(4) (Posted: Nov 14, 2018 11AM)

Precision medicine in oncology: what is it exactly and where are we?
Le Tourneau Christophe et al. Personalized medicine 2018 Sep (Posted: Oct 03, 2018 8AM)

Why Does the Shift from "Personalized Medicine" to "Precision Health" and "Wellness Genomics" Matter?
Juengst Eric T et al. AMA journal of ethics 2018 Sep 20(9) E881-890 (Posted: Sep 26, 2018 10AM)

Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine.
Maugeri Andrea et al. BioMed research international 2018 20187532507 (Posted: Sep 19, 2018 9AM)

Enhancing diversity to reduce health information disparities and build an evidence base for genomic medicine.
Hindorff Lucia A et al. Personalized medicine 2018 Sep (Posted: Sep 19, 2018 9AM)

Biorepository and integrative genomics initiative: designing and implementing a preliminary platform for predictive, preventive and personalized medicine at a pediatric hospital in a historically disadvantaged community in the USA.
Jose Rony et al. The EPMA journal 2018 Sep 9(3) 225-234 (Posted: Sep 05, 2018 9AM)

Design of a Controlled Trial of Cascade Screening for Hypercholesterolemia: The (CASH) Study.
Kullo Iftikhar J et al. Journal of personalized medicine 2018 Aug 8(3) (Posted: Aug 29, 2018 10AM)

From hype to reality: data science enabling personalized medicine.
Fröhlich Holger et al. BMC medicine 2018 Aug 16(1) 150 (Posted: Aug 29, 2018 9AM)

Preface to Special Issue on 'Cytochrome P450 Variation in Pharmacogenomics'.
Rettie Allan E et al. Journal of personalized medicine 2018 Jul (3) (Posted: Aug 09, 2018 10AM)

Early Outcome Data Assessing Utility of a Post-Test Genomic Counseling Framework for the Scalable Delivery of Precision Health.
Sturm Amy C et al. Journal of personalized medicine 2018 Jul 8(3) (Posted: Aug 01, 2018 10AM)

Risk biomarkers enable precision in public health.
Ollier William et al. Personalized medicine 2018 Jun (Posted: Jul 03, 2018 11AM)

The Undergraduate Training in Genomics (UTRIG) Initiative: early & active training for physicians in the genomic medicine era.
Wilcox Rebecca L et al. Personalized medicine 2018 May (Posted: Jun 11, 2018 11AM)

Putting The Person In Personalized Medicine
CH Wilkins, Health affairs, May 2018 (Posted: May 08, 2018 8AM)

The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
Eckford Paul D W et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2018 Apr (Posted: May 02, 2018 9AM)

The DNA Data We Have Is Too White. Scientists Want to Fix That- In an era of personalized medicine, not including minorities in genetic studies has real-world health impacts
Smithsonian Magazine, Apr 30, 2018 (Posted: Apr 30, 2018 2PM)

Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.
Gaedigk Andrea et al. Journal of personalized medicine 2018 Apr 8(2) (Posted: Apr 25, 2018 9AM)

Pharmacogenetics and the Promise of Personalized Medicine
MS Sabatine, JAMA Cardiology, Mar 11, 2018 (Posted: Mar 11, 2018 6PM)

Diabetes Is Five Diseases, Not Two The new classification system could help improve personalized medicine approaches to the disease
J Daily, the Scientist, Mar 5, 2018 (Posted: Mar 05, 2018 10AM)

Will Personalized Medicine Mean Higher Costs for Consumers?
M Geruso et al, Harvard Business Review, Mar 1, 2018 (Posted: Mar 02, 2018 10AM)

The use of omics profiling to improve outcomes of bone regeneration and osseointegration. How far are we from personalized medicine in dentistry?
Calciolari E et al. Journal of proteomics 2018 Feb (Posted: Feb 27, 2018 9AM)

Screening for rare genetic variants associated with atherosclerosis: opportunity for personalized medicine.
Peterlin Ana et al. Current vascular pharmacology 2018 Feb (Posted: Feb 14, 2018 11AM)

Taking personalized medicine to heart.
et al. Nature medicine 2018 Feb (2) 113 (Posted: Feb 14, 2018 10AM)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.
Brown Sherry-Ann et al. Journal of personalized medicine 2018 Jan (1) (Posted: Feb 06, 2018 0PM)

What Does Personalized Medicine Really Mean?
L Esposito, US News, Jan 26, 2018 (Posted: Feb 02, 2018 11AM)

Personalized Medicine in CF: From Modulator Development to Therapy for Cystic Fibrosis Patients with Rare CFTR Mutations.
Harutyunyan Misak et al. American journal of physiology. Lung cellular and molecular physiology 2017 Dec (Posted: Jan 24, 2018 10AM)

Frontiers in Precision Medicine III –Will Personalized Medicine Improve Population Health?
Frontiers in Precision Medicine, University of Utah, March 16, 2018 (Posted: Jan 21, 2018 9AM)

Engineering precision biomaterials for personalized medicine.
Aguado Brian A et al. Science translational medicine 2018 Jan (424) (Posted: Jan 19, 2018 2PM)

Microbiome at the Frontier of Personalized Medicine.
Kashyap Purna C et al. Mayo Clinic proceedings 2017 Dec (12) 1855-1864 (Posted: Jan 06, 2018 6AM)

Representing a "revolution": how the popular press has portrayed personalized medicine.
Marcon Alessandro R et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 Jan (Posted: Jan 05, 2018 7AM)

The future of telomere length in personalized medicine.
Gorenjak Vesna et al. Frontiers in bioscience (Landmark edition) 2018 Mar 231628-1654 (Posted: Jan 03, 2018 10AM)

The role of epigenomics in personalized medicine.
Kronfol Mohamad M et al. Expert review of precision medicine and drug development 2017 2(1) 33-45 (Posted: Jan 03, 2018 10AM)

more


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP